Roivant Sciences Ltd. (NASDAQ:ROIV) Q2 2024 Earnings Call Transcript
Q2 2024 Earnings Call Transcript November 12, 2024 Operator: Good day and thank you for standing by. Welcome to the Roivant ...
Finanznachrichten47m
Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Results of Tenax Therapeutics' Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that IV ...
Gyre Therapeutics, Inc.: Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis ...